To explore risk factors of proteinuria events in bevacizumab(BEV)-treated patients with metastatic colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).

The medical records of patients with CRC and NSCLC who received BEV combined with standard chemotherapy regimen in Zhongshan Hospital Affiliated to Fudan University from September 2016 to December 2017 were collected and analyzed retrospectively.

A total of 252 patients were enrolled into the study, including 166 males (65.9%) and 86 females (34.1%), aged 23-81 years with the average age of (58±11) years. One hundred and fifty-one patients were diagnosed with CRC, 101 patients were diagnosed with NSCLC, and the median cycle of the BEV treatment was 9 (1-30). The incidence of all-grade proteinuria during BEV treatment was 23.8% (60/252). The risk of proteinuria occurrence increased with aging, and patients ≥ 65 years old had the highest risk (OR=3.769, 95%CI: 2.060-6.895, P<0.001). The risk of proteinuria was also significantly increased in patients having received ≥7 cycles of BEV treatment, and the highest risk existed in patients having received ≥10 cycles of BEV treatment (OR=3.769, 95%CI: 2.060-6.895, P<0.001). The risk of BEV-associated proteinuria increased in CRC or NSCLC patients with hypertension (OR=2.189, 95%CI: 1.214-3.945, P=0.008).

The main risk factors of BEV-related proteinuria events in patients with CRC or NSCLC were aging ( ≥65 years old), complicated with hypertension, and receiving ≥7 cycles of BEV treatment. Urine routine and renal function monitoring should be strengthened in patients with above risk factors during their BEV treatments.

Bevacizumab; Drug-related side effects and adverse reactions; Proteinuria; Risk factors; Colorectal neoplasms; Carcinoma, non-small-cell lung